Cell-lines that are established models for numerous indications including lung carcinoma (A549) or human neuronal precursor cells (ReNcell CX®) were used for treatment experiments to reveal the potential efficacy of NVP-13 to target several TGFβ dependent disorders. Here, TGFB1 is linked to lung carcinoma.